Literature DB >> 26002818

Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study.

Jörg Otto Schwab1, Hendrik Bonnemeier2, Thomas Kleemann3, Johannes Brachmann4, Sven Fischer5, Frank Birkenhauer6, Frank Eberhardt7.   

Abstract

BACKGROUND: A significant number of patients with an implantable cardioverter/defibrillator (ICD) for primary prevention receive inappropriate shocks. Previous studies have reported a reduction of inappropriate therapies with simple modifications of ICD detection settings, however, inclusion criteria and settings varied markedly between studies. Our aim was to investigate the effect of raising the ICD detection zone in the entire primary prevention ICD population. METHODS AND
RESULTS: 543 patients receiving an ICD for primary prevention were randomized to either conventional or progressive ICD programming. The detection rate was programmed at 171 bpm for ventricular tachycardia (VT) and 214 bpm for ventricular fibrillation (VF) in the Conventional group and 187 bpm for VT and 240 bpm for VF in the Progressive group. 43 % of patients received single-chamber and 57 % dual-chamber detection devices (DDD-ICD 19 %; CRT-D 38 %). The primary endpoint consisted of inappropriate therapies and untreated VT/VF. The primary endpoint was reached in 35 patients (13 %) in the Conventional group and 17 patients (6 %) in the Progressive group (p = 0.004). Progressive ICD programming led to significantly fewer amount of patients with ICD therapies (26 vs. 14 %; p < 0.001) and shocks (11 vs. 5 %; p = 0.023) compared to conventional ICD programming. Sub-analyses showed the greatest reduction of inappropriate therapies and shocks in dual-chamber detection devices with progressive compared to single-chamber detection devices with conventional ICD programming (p < 0.001).
CONCLUSIONS: Progressive ICD programming reduces the number of inappropriate therapies and shocks in a broad primary prevention ICD population particularly in combination with dual-chamber detection algorithms. CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov ; ClinicalTrials.gov identifier NCT01217528.

Entities:  

Keywords:  Implantable cardioverter defibrillator; Inappropriate therapy; Primary prevention; Sudden cardiac death

Mesh:

Year:  2015        PMID: 26002818     DOI: 10.1007/s00392-015-0870-z

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  27 in total

1.  2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Authors:  Kenneth Dickstein; Panos E Vardas; Angelo Auricchio; Jean-Claude Daubert; Cecilia Linde; John McMurray; Piotr Ponikowski; Silvia Giuliana Priori; Richard Sutton; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

2.  Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.

Authors:  Paul A Friedman; Robyn L McClelland; William R Bamlet; Helbert Acosta; David Kessler; Thomas M Munger; Neal G Kavesh; Mark Wood; Emile Daoud; Ali Massumi; Claudio Schuger; Stephen Shorofsky; Bruce Wilkoff; Michael Glikson
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

3.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2008-05-15       Impact factor: 29.690

4.  Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery.

Authors:  B Healy; L Campeau; R Gray; J A Herd; B Hoogwerf; D Hunninghake; G Knatterud; W Stewart; C White
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

5.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Comparing outcome of patients with coronary artery disease and dilated cardiomyopathy in ICD and CRT recipients: data from the German DEVICE-registry.

Authors:  Kristina Wasmer; Julia Köbe; Dietrich Andresen; Ralf Zahn; Stefan G Spitzer; Joachim Jehle; Johannes Brachmann; Christoph Stellbrink; Eimo Martens; Matthias Hochadel; Jochen Senges; Helmut Klein; Lars Eckardt
Journal:  Clin Res Cardiol       Date:  2013-03-30       Impact factor: 5.460

8.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

9.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

10.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

View more
  7 in total

1.  Reduction of inappropriate implantable cardioverter-defibrillator therapies using enhanced supraventricular tachycardia discriminators: the ReduceIT study.

Authors:  Johann Christoph Geller; Armin Wöhrle; Mathias Busch; Albrecht Elsässer; Thomas Kleemann; Frank Birkenhauer; Peter Bramlage; Christian Veltmann
Journal:  J Interv Card Electrophysiol       Date:  2020-07-14       Impact factor: 1.900

2.  Right versus left parasternal electrode position in the entirely subcutaneous ICD.

Authors:  Markus Bettin; Dirk Dechering; Gerrit Frommeyer; Robert Larbig; Andreas Löher; Florian Reinke; Julia Köbe; Lars Eckardt
Journal:  Clin Res Cardiol       Date:  2017-12-28       Impact factor: 5.460

Review 3.  Detection and discrimination of tachycardia in ICDs manufactured by St. Jude Medical.

Authors:  Jan Zdarek; Carsten W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-09-07

4.  The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.

Authors:  Leon Dinshaw; Julia Münch; Jannis Dickow; Susanne Lezius; Stephan Willems; Boris A Hoffmann; Monica Patten
Journal:  Clin Res Cardiol       Date:  2017-09-30       Impact factor: 5.460

Review 5.  Programming implantable cardioverter/defibrillators and outcomes.

Authors:  Fritz W Horlbeck; Joerg O Schwab
Journal:  F1000Prime Rep       Date:  2015-01-05

Review 6.  Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis.

Authors:  Angelo Auricchio; J Harrison Hudnall; Edward J Schloss; Laurence D Sterns; Takashi Kurita; Albert Meijer; Dedra H Fagan; Tyson Rogers
Journal:  Europace       Date:  2017-12-01       Impact factor: 5.214

7.  Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.

Authors:  Robert T Greenlee; Alan S Go; Pamela N Peterson; Andrea E Cassidy-Bushrow; Charles Gaber; Romel Garcia-Montilla; Karen A Glenn; Nigel Gupta; Jerry H Gurwitz; Stephen C Hammill; John J Hayes; Alan Kadish; David J Magid; David D McManus; Deborah Multerer; J David Powers; Liza M Reifler; Kristi Reynolds; Claudio Schuger; Param P Sharma; David H Smith; Mary Suits; Sue Hee Sung; Paul D Varosy; Humberto J Vidaillet; Frederick A Masoudi
Journal:  J Am Heart Assoc       Date:  2018-03-26       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.